Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma

设为首页

收藏本站

网站地图 | English | 公务邮箱

About the library

Background
History
Leadership
Organization

Readers' Guide

Opening Hours
Collections
Help Via Email

Publications

Electronic Information Resources

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma

详细信息查看全文

作者：Dirk Schadendorf^a ; ^{dirk.schadendorf@uk-essen.de" class="auth_mail" title="E-mail the corresponding author} ; Reinhard Dummer^b ; ^{Reinhard.Dummer@usz.ch" class="auth_mail" title="E-mail the corresponding author} ; Axel Hauschild^c ; ^{ahauschild@dermatology.uni-kiel.de" class="auth_mail" title="E-mail the corresponding author} ; Caroline Robert^d ; ^{Caroline.Robert@gustaveroussyr.fr" class="auth_mail" title="E-mail the corresponding author} ; Omid Hamid^e ; ^{ohamid@theangelesclinic.org" class="auth_mail" title="E-mail the corresponding author} ; Adil Daud^f ; ^{Adil.Daud@ucsf.edu" class="auth_mail" title="E-mail the corresponding author} ; Alfons van den Eertwegh^g ; ^{vandeneertwegh@VUMC.nl" class="auth_mail" title="E-mail the corresponding author} ; Lee Cranmer^h ; ^{lcranmer@uacc.arizona.edu" class="auth_mail" title="E-mail the corresponding author} ; Steven O'Dayⁱ ; ^{stevenjoday@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Igor Puzanov^j ; ^{igor.puzanov@vanderbilt.edu" class="auth_mail" title="E-mail the corresponding author} ; Jacob Schachter^k ; ^{Jacob.Schachter@sheba.health.gov.il" class="auth_mail" title="E-mail the corresponding author} ; Christian Blank^l ; ^{c.blank@nki.nl" class="auth_mail" title="E-mail the corresponding author} ; April Salama^m ; ^{april.salama@duke.edu" class="auth_mail" title="E-mail the corresponding author} ; Carmen Loquaiⁿ ; ^{carmen.loquai@unimedizin-mainz.de" class="auth_mail" title="E-mail the corresponding author} ; Janice M. Mehnert^o ; ^{mehnerja@cinj.rutgers.edu" class="auth_mail" title="E-mail the corresponding author} ; Darcy Hille^p ; ^{darcy_hille@merck.com" class="auth_mail" title="E-mail the corresponding author} ; Scot Ebbinghaus^p ; ^{scot_ebbinghaus@merck.com" class="auth_mail" title="E-mail the corresponding author} ; S. Peter Kang^p ; ^{s.peter.kang@merck.com" class="auth_mail" title="E-mail the corresponding author} ; Wei Zhou^p ; ^{wei.zhou2@merck.com" class="auth_mail" title="E-mail the corresponding author} ; Antoni Ribas^q ; ^{aribas@mednet.ucla.edu" class="auth_mail" title="E-mail the corresponding author}
关键词：Pembrolizumab ; Patient-reported outcomes ; Health-related quality of life ; KEYNOTE-002 ; Advanced melanoma ; Ipilimumab-refractory melanoma ; Chemotherapy ; EORTC QLQ-C30
刊名：European Journal of Cancer
出版年：2016
出版时间：November 2016
年：2016
卷：67
期：Complete
页码：46-54
全文大小：579 K

文摘

class="label">•: Health-related quality of life (HRQoL) was evaluated in the KEYNOTE-002 study.
class="label">•: HRQoL was maintained to a greater degree with pembrolizumab versus chemotherapy.
class="label">•: In all arms, HRQoL decreased in patients who experienced disease progression.
class="label">•: These data support pembrolizumab for ipilimumab-refractory advanced melanoma.